Faron Pharmaceuticals reported cash and cash equivalents of EUR 32.0 million at 30 June, more than double the EUR 13.5 million held a year earlier.
The AIM-quoted biotech, which is developing bexmarilimab, an antibody therapy designed to reprogram myeloid cells to activate anti-tumour immunity, highlighted that its stronger balance sheet follows a EUR 40.1 million rights issue completed in April.
That was one of Finland's largest biotech financings, which the company says now funds preparations for the randomized Phase 2b BEXERA trial.
That trial, supported by a collaboration with clinical research organisation Parexel agreed in April, will enrol 90 patients across up to 35 sites in the US, Europe and the UK to select a recommended Phase 3 dose for bexmarilimab combined with azacitidine in frontline higher-risk MDS.
Net assets swung to EUR 11.6 million from a deficit of EUR 16.7 million a year earlier. The operating loss narrowed slightly to EUR 11.1 million from EUR 11.8 million, while research and development spending rose to EUR 7.6 million from EUR 7.1 million. Loss per share fell to EUR 0.06 from EUR 0.18.
In June, Faron presented matured data from its BEXMAB study at the European Hematology Association Congress, showing median duration of complete remission extended to 16.1 months in treatment-naive higher-risk MDS patients on bexmarilimab plus azacitidine.
"With our strengthened balance sheet, we are well positioned to advance the program, generate further clinical evidence and maintain strategic flexibility while continuing partnering discussions," said chief executive Juho Jalkanen.
The BEXERA trial is planned to begin in the second half of 2026.
News Intelligence what this means for the company
Faron doubled its cash to EUR 32 million via a EUR 40.1 million rights issue in April, erasing a prior net asset deficit of EUR 16.7 million and swinging to EUR 11.6 million in net assets. The capital raise directly funds the Phase 2b BEXERA trial, which will enrol 90 patients across 35 sites to select a Phase 3 dose of bexmarilimab plus azacitidine in frontline higher-risk MDS, launching in H2 2026—a material de-risking step anchored by matured Phase 1/2 data showing 16.1-month median complete remission duration in treatment-naïve patients.
The raise extends runway into Phase 2b readouts and eliminates near-term dilution risk, but success hinges on BEXERA's ability to replicate Phase 1/2 efficacy in a randomized setting and identify a dose that advances to Phase 3—a binary inflection point 18–24 months away.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
